Chinese pharmaceutical company Huapont Life Sciences has announced plans to acquire 48.3% stake in a local tourist firm from a controlling shareholder.
Huapont is engaged in manufacturing and marketing active pharmaceutical ingredients (APIs) and finished doses.
The acquisition will involve a purchase consideration of ¥139.4m ($21.47m).
Sosei Group has reached an agreement to acquire 25.6% stake in MiNA Therapeutics, and an option to acquire further defined stakes to eventually fully acquire the target company.
The purchase consideration for the 25.6% stake acquisition is £35m ($45.2m). A further £140m ($180.83m) is payable in the event of 100% acquisition, as part of the agreement.
The target company’s shareholders could further receive up to £240m ($310m) upon achievement of development and regulatory milestones.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData